Date: 2012-11-14
Type of information: R&D agreement
Compound: Transcend technology
Company: biOasis Technologies (Canada) MedImmune (USA - global biologics arm of AstraZeneca (UK)
Therapeutic area:
Type agreement: R&D
Action mechanism:
Disease: Transcend technology is based on p97 (melanotransferrin). p97 can be used to deliver therapeutics agents through the Blood Brain Barrier (BBB). Brain capillaries, that comprise the BBB, possess an endogenous receptor that ferries an iron-transport protein, termed p97 (melanotransferrin), across the BBB.
Details: biOasis Technologies has entered into a research and evaluation agreement with MedImmune, the global biologics arm of AstraZeneca. Under the terms of this collaboration, biOasis will conduct certain experiments at MedImmune’s expense with the objective of demonstrating that biOasis’s Transcend technology can deliver to the brain compounds of interest to MedImmune.
Financial terms: Financial terms were not disclosed.
Latest news:
